Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial
Borlaug BA, Jensen MD, Packer M, et al. (2026). Nature Medicine.
Summary
A double-blind, placebo-controlled randomised trial (CAMEO-SEMA, NCT05371496) in 81 adults with obesity-related heart failure with preserved ejection fraction. After 52 weeks, weekly semaglutide lowered exercise pulmonary artery wedge pressure by 10.6 mmHg more than placebo (95% confidence interval -13.3 to -8.0). Normal pressures at rest and during exercise were reached by 53.7% of the semaglutide group, compared with 7.4% on placebo, and resting pressure was 7.1 mmHg lower than placebo. It is a small, mechanism-focused trial from the Mayo Clinic, supported by the US Department of Defense; semaglutide and matching placebo were supplied by Novo Nordisk. The senior author also reports research funding from, and consultancy for, Novo Nordisk. A companion cardiac MRI substudy in 49 participants from the same trial reported improved left-atrial function and left-ventricular filling (doi:10.1038/s41591-026-04787-8).
Peptides in this study
Semaglutide in the United Kingdom · Semaglutide in the United States · Semaglutide in Australia